Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Axiom Investors LLC DE

Key Points

• Axiom Investors LLC DE has reduced its stake in Supernus Pharmaceuticals by 22.2% during the first quarter, owning 54,375 shares valued at approximately $1.78 million after selling 15,521 shares.
• Multiple institutional investors have increased their positions in Supernus Pharmaceuticals recently, with Barclays PLC raising its stake by 12.9% during the fourth quarter, now holding 122,849 shares.
• Supernus Pharmaceuticals has received upgrades from analysts, including a change from a "strong sell" to a "hold" rating by Zacks Research and a new price target of $46.00 set by Cantor Fitzgerald.

Axiom Investors LLC DE decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,375 shares of the specialty pharmaceutical company's stock after selling 15,521 shares during the quarter. Axiom Investors LLC DE owned approximately 0.10% of Supernus Pharmaceuticals worth $1,781,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after acquiring an additional 1,083 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Supernus Pharmaceuticals by 14.7% in the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after buying an additional 1,000 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after buying an additional 9,590 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Supernus Pharmaceuticals by 6.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after purchasing an additional 3,495 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after purchasing an additional 6,867 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SUPN shares. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Piper Sandler increased their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday. Finally, Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the transaction, the chief financial officer owned 1,246 shares of the company's stock, valued at approximately $55,434.54. This trade represents a 90.43% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 179,606 shares of company stock worth $7,617,005. Insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN traded down $0.23 during mid-day trading on Friday, hitting $45.14. 329,274 shares of the company's stock traded hands, compared to its average volume of 637,786. The company has a market capitalization of $2.53 billion, a P/E ratio of 39.25 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $45.60. The company's 50-day moving average is $36.37 and its two-hundred day moving average is $33.90.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.